drugset / Trial / NCT02728726
Sugammadex vs Placebo to Prevent Residual Neuromuscular Block
Phase 4
Completed
260 enrolled
Mayo Clinic
Merck Sharp & Dohme LLC · collabRespiratory Motion, Inc. · collabUniversity of Texas · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is designed to determine whether patients who receive sugammadex immediately after tracheal extubation will exhibit a decrease in the incidence of postoperative residual paralysis and an associated decrease in the incidence of postoperative respiratory depression.
Timeline
- Start
- 2016-06
- Primary completion
- 2019-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sugammadex | Other / unclassified | 2 mg/kg | Intravenous |
Indications
No indication recorded.